ArticleFrontiers in cardiovascular medicine2022
A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Cardiac fibrosis: mechanistic insights and translational advances.Molecular biomedicine · 2026Review
- Next-generation molecular imaging of cardiac fibrosis.The international journal of cardiovascular imaging · 2026Review
- Application of Radionuclide Myocardial Imaging in the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction.Reviews in cardiovascular medicine · 2025Review
- Total-body positron emission tomography: Investigating mechanisms in cardiovascular-kidney-metabolic syndrome.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Review
- Mechanisms of diabetic cardiomyopathy: Focus on inflammation.Diabetes, obesity & metabolism · 2025Review
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET).Npj imaging · 2024Review
- [Clinical kidney journal · 2024Article
- Recent Progresses in the Multimodality Imaging Assessment of Myocardial Fibrosis.Reviews in cardiovascular medicine · 2024Review
- A biomarker framework for cardiac aging: the Aging Biomarker Consortium consensus statement.Life medicine · 2023Article
- Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases.Journal of clinical medicine · 2023Review
- The Potential of Fibroblast Activation Protein-Targeted Imaging as a Biomarker of Cardiac Remodeling and Injury.Current cardiology reports · 2023Review
- Gallium-68 fibroblast activation protein inhibitor positron emission tomography in cardiovascular disease.Frontiers in nuclear medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: FAP plays a vital role in myocardial injury and fibrosis. Although initially used to study imaging of primary and metastatic tumors, the use of FAPI tracers has recently been studied in cardiac remodeling after myocardial infarction. The study aimed to investigate the application of FAPI PET/CT imaging in human myocardial fibrosis and its relationship with clinical factors. Materials and methods: Retrospective analysis of FAPI PET/CT scans of twenty-one oncological patients from 05/2021 to 03/2022 with visual uptake of FAPI in the myocardium were applying the American Heart Association 17-segment model of the left ventricle. The patients' general data, echocardiography, and laboratory examination results were collected, and the correlation between PET imaging data and the above data was analyzed. Linear regression models, Kendall's TaU-B test, the Spearman test, and the Mann-Whitney Results: 21 patients (60.1 ± 9.4 years; 17 men) were evaluated with an overall mean LVEF of 59.3 ± 5.4%. The calcific plaque burden of LAD, LCX, and RCA are 14 (66.7%), 12 (57.1%), and 9 (42.9%). High left ventricular SUVmax correlated with BMI ( Conclusion: FAPI PET/CT scans might be used as a new potential method to evaluate cardiac fibrosis to help patients' management further. FAPI PET imaging can reflect the process of myocardial fibrosis. High FAPI uptakes correlate with cardiovascular risk factors and the distribution of coronary plaques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.